anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for manufacturing an antidotal food product containing activated charcoal is provided to combine a binder, a filler composition, water, flavoring and sweetener compositions with an activated charcoal to form wafers having a consistency emulating that of a baked cookie. The activated charcoal ( 110 ), binder ( 112 ), filler ( 114 ), water ( 116 ), and flavoring and sweetener compositions ( 118 ) are combined in a mixer ( 210 ) to form a slurry. The slurry is then processed in a spray dryer ( 220 ) to form granules. The granules are combined with a lubricant ( 122 ) in a blender ( 230 ). The dry mixture from blender ( 230 ) is then formed into wafers by a tableting type machine in a compression molding step ( 240 ). The wafers formed in the compression molding step ( 240 ) are then coated in an anti-dusting coating step ( 250 ). A sweet creme filling is applied between pairs of the wafers in a cookie sandwich assembly step ( 270 ).
All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
Participants in this group will use the tested device to perform 2 x 10-minute of aerobic training (cycling in the hospital) interspersed with a 5-minute break. Exercise intensity will be of 2/10 on the Borg scale of perceived exertion (around 3 +/- 2 watts at 20 rpm).
Similarly, in the control group (30 participants),visual analog scale (VAS) pain scores were evaluated when the pain started on the first three days of their menstruation, and their blood pressure, body temperature, and pulse rate were measured. No application was performed; they were only asked to rest. VAS evaluation and blood pressure, body temperature, and pulse rate measurements were performed again after 30 minutes. These measurements were repeated for two menstrual cycles.
The invention belongs to the field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition and a traditional Chinese medicine preparation for improving gout, and a preparation method and application thereof. The traditional Chinese medicine composition for improving gout is prepared from the following medicinal materials in parts by weight: 6-13 parts of rhizoma atractylodis, 6-13 parts of amur corktree bark, 5-13 parts of medicinal cyathula root, 22-37 parts of coix seed, 13-25 parts of yam rhizome, 10-20 parts of oriental waterplantain rhizome, 10-20 parts of glabrous greenbrier rhizome, 5-12 parts of herba lycopi and 5-12 parts of sappan wood. The Chinese medicinal composition is prepared from cortex Phellodendri, rhizoma Atractylodis, coicis semen and Achyranthis radix, and has effects of clearing heat and promoting diuresis. Rhizoma Dioscoreae Septemlobae and rhizoma Smilacis Glabrae have effects of clearing away heat and dampness, dredging joint, removing arthralgia, and relieving pain, and are ministerial drugs. Sappan wood and herba lycopi have the effects of promoting blood circulation to remove blood stasis, relaxing tendons and activating collaterals, and relieving swelling and pain, and are guiding drugs. Alismatis rhizoma is good at dispelling heat, promoting urination, and promoting excretion of damp-heat, and is a guiding drug. The medicines are combined to clear damp-heat and remove swelling and pain, and have good effects on improving gout.
A method for enhancing or restoring lacrimal function by the topical administration of a cyclosporin in a pharmaceutically acceptable excipient. Lacrimal function is enhanced or restored in patients suffering from abnormalities of the tear film including an absolute or partial deficiency in aqueous tear production, called keratoconjunctivitis sicca or KCS, regardless of etiology, including autoimmune dysfunction of the lacrimal glands. The treatment is also useful in the enhancement or restoration of normal tear production, and normal healing of the surface of the eye. The preferred composition for topical administration to the eye consists of cyclosporin dissolved in corn oil. The composition may further include antioxidants, lubricants, antibiotics, antifungals, antivirals, pilocarpine, vasoconstrictors, surfactants, wetting agents, anti-inflammatory agents (i.e. corticosteroids), preservatives, mucolytic agents (i.e. bromhexine, acetylcysteine), as well as other compounds. The most preferred composition is 2% cyclosporin, 1 mole % alpha tocopherol and 0.005% methyl paraben in corn oil.
The invention relates to a traditional Chinese medicinal composition for treating cholelith and renal lithiasis, and the composition employs compatibility of herb of marginate rockbell, cantharis and chicken bile. The composition aims at the general characters of moisture, heat, blood stasis and retention in the etiology and pathogenesis of the two diseases and the common requirements of passing down and smoothing, so that the composition can sure two diseases. However, different administration methods are employed according to the differences of the two diseases, so as to cure the diseases quickly and safely. The invention adopts compatibility of herb of marginate rockbell, cantharis and chicken bile, and is supplemented with Christina Loosestrife herb for frequent delivery as tea; and for cholelith, herba glechomae is employed, and for renal lithiasis, herb of creeping dichondra is used. A patient should drink the medicinal composition as tea as many as possible. The composition has less medicinal taste and sophisticated and specialized medicinal efficacy, can break stagnation, treat stranguria, and induce urination; and the composition is taken with Christina Loosestrife herb tea to ensure fast and safe breaking and expelling of stones, and avoid toxic and side effects.
FIELD: gynecological endocrinology. SUBSTANCE: one introduces thyroid hormones, for instance L-thyroxin, in maximum tolerable doses during 3 to 12 months and determines therapeutic efficiency from integrated estimation of mastopathy remission. After termination of the course, enzyme or vitamin therapy is performed. When mastalgia is observed, one orders therapy designed to correct failed function of endocrine glands revealed during complex examination before treatment taking into account data obtained during examination of woman after treatment. EFFECT: enabled partial remission of endocrinal organs and complete mastopathy remission with restoration of lutein phase of ovulatory ovary cycle. 2 tbl, 3 ex
AC-T chemotherapy includes 4 cycles of doxorubicin and cyclophosphamide given every 2 or 3 weeks followed by either 12 weekly cycles of lower dose paclitaxel or 4 cycles of higher dose paclitaxel every 2 or 3 weeks. During this time, all participants would receive daily aspirin and daily tamoxifen. After the AC-T chemotherapy, participants will undergo standard of care surgery to remove any remaining tumor.
Low back pain is a widespread public health concern owing to its high prevalence rates according to the Global Burden of Diseases. This study aimed to investigate the effect of exercise alone or in combination with manual therapy and kinesiotherapy on pain sensitivity, disability, kinesiophobia, self-efficacy, and catastrophizing in patients with chronic low back pain (CLBP). A total of 55 participants were enrolled and randomly allocated to one of three groups: (1) exercise alone group (ET; n = 19), (2) exercise + manual therapy group (ETManual therapy; n = 18), and (3) exercise + kinesio tape group (ETkinesiotape; n = 18). The interventions consisted of core stabilization exercises (ET group), prior spinal manipulation with core exercises (ETManual therapy group), and combined application of kinesiotape plus core stabilization exercises (ETkinesiotape group). The primary outcome was disability. The secondary outcomes were pain sensitization, kinesiophobia, catastrophizing, and self-efficacy. Assessments were performed at baseline and at weeks 3, 6, and 12. All therapies applied achieved significant improvements over time after 12 weeks in all parameters analyzed. ETmanualtherapy showed the greatest changes in all variables, with significant differences from the rest of the interventions in Oswestry (ODI) (3 and 6 weeks, respectively). A clinically significant cutoff point was achieved for the ETmanualtherapy group in the ODI parameter (-54.71%, -63.16% and -87.70% at 3, 6, and 12 weeks, respectively). Manual therapy prior to the core exercise technique was the most effective approach to improve health-related functionality compared with exercise alone or exercise combined with kinesiotape in patients with CLBP.Clinical Trial Registration Number: NCT05544890.
A method for purifying bone-derived TGF-β proteins including an anion exchange process, a cation exchange process, and a reverse phase HPLC process, and optionally, a filtration process, a Heparin-Sepharose process, and/or a reverse phase HPLC desalting process. The filtration process preferably selects proteins having a nominal molecular weight between approximately 10 kilodaltons and approximately 100 kilodaltons. Preferably, the anion exchange process uses a strongly cationic resin having quaternary amine functional groups. Preferably, the cation exchange process uses a strongly anionic resin having sulfonic acid functional groups. The TGF-β proteins can be eluted from the reverse phase HPLC column with an acetonitrile solution in combination with aqueous trifluoracetic acid. The purification processes yield highly enriched TGF-β1 and TGF-β2 proteins.
BACKGROUND: Robot-assisted radical prostatectomy (RARP) is a standard treatment for localized prostate cancer. We previously reported that a large amount of pelvic visceral fat and a small working space, as measured by three-dimensional image analysis, were significantly associated with prolonged console time in RARP, and these factors could be alternatives to the more clinically practical body mass index (BMI) and pelvic width (PW), respectively. Herein, we further investigated whether surgical proficiency affected surgical difficulty as measured by console time.
METHODS: Medical records of 413 patients who underwent RARP between 2014 and 2020 at our institution were reviewed. Surgeons who had experience with over and under 100 cases were defined as "experienced" and "non-experienced," respectively. Multivariate logistic regression analyses were performed to identify factors that prolonged console time.
RESULTS: The median console times for RARP by experienced and non-experienced surgeons were 87.5 and 149.0 min, respectively; a difficult case was defined as one requiring time greater than the median. Among inexperienced surgeons, higher BMI (p < 0.001, odds ratio: 1.89) and smaller PW (p = 0.001, odds ratio: 1.86) were significant factors that increased console time; the complication rate was increased in patients with these factors. However, these factors did not significantly affect the console time or complication rate among experienced surgeons.
CONCLUSION: This study demonstrates that experienced surgeons may be able to overcome obesity- and small workspace-related surgical difficulties. The current analysis may provide useful information regarding unpredictable surgical risks and identify suitable cases for novices.
Major depressive disorder (MDD) is a severe form of depression. MDD can significantly interfere with an individual's thoughts, behavior, mood, and physical health. People who suffer from MDD often experience feelings of worthlessness; they may feel hopeless and may be unable to cope with problems in their life. In addition, they often experience sleep disruption, loss of appetite, and chronic pain.

Antidepressant medications are often prescribed for treating MDD; however, 30% to 40% of individuals fail to respond adequately to medication. Preliminary research has shown that lower levels of brain energy metabolism are often associated with MDD. No studies have yet shown whether there is a difference in brain energy metabolism between individuals who respond well to antidepressants versus those who do not. Escitalopram is an antidepressant medication often used to treat MDD. It causes a calming effect and reduces anxiety by increasing the amount of serotonin in the brain. This study will compare the changes in brain energy metabolism due to treatment with escitalopram in individuals with MDD. In turn, these findings may aid in understanding the relationship between brain energy metabolism and depression, and may guide future antidepressant trials.

This 12-week study will enroll individuals diagnosed with MDD, as well as healthy individuals. During Weeks 1 through 4, participants with MDD will receive 10 mg of escitalopram on a daily basis. If a participant does not respond well to the medication, as determined by the study clinician, the dose may be increased to 20 mg per day for Weeks 5 through 8. If a participant continues to not respond to the medication after 8 weeks, the dose may be increased to 30 mg per day for Weeks 9 through 12. Study visits will occur every other week throughout the 12 weeks. Laboratory tests, physical examinations, and vital sign measurements will be performed at each study visit. Outcome measurements will include depression levels as assessed by standardized psychological tests and questionnaires, as well as brain energy metabolite levels as assessed by magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) scans. The MRS and MRI scans will occur at baseline, Week 2, and Week 12; the entire scanning procedure will last 70-80 minutes. Following the end of the study, all participants will be offered follow-up medical care for 3 months. Participants who responded well to escitalopram will be offered continued treatment with the drug, while those who did not respond well to escitalopram will be offered treatment with another antidepressant.
Participants will receive roxadustat orally (or via gastric tube as an aqueous dispersion, if necessary) 3 times per week. The 24-week treatment period is defined as 4 weeks of fixed dose treatment followed by 20 weeks of dose titration(s). Dose titrations will be based on hemoglobin (Hb) monitoring. Participants in the study may receive roxadustat treatment for up to 52 weeks.
This is a two-arm, parallel assignment, open-label, randomized control trial comparing back pain outcomes in an intervention group (MPT using the Kaia app) to those of a control group (usual care without restrictions on treatment). It is designed to enroll up to 184 participants. The treatment period will last for 90 days. This includes the randomization assignment and follow-up evaluations at 30 days, 60 days, and 90 days post-randomization. After pre-screening and informed consent activities are completed, the study will be conducted using electronic patient reported outcomes (ePROs); participants can complete all study tasks at home by means of internet-enabled devices. Participants assigned to the intervention group will implement Kaia's exercise regimen using their personal mobile devices. The control group will receive usual care without restrictions and will be provided with internet-based information about treatment of non-specific back pain, including handouts depicting typical home-based exercises as recommended by American Academy of Orthopedic Surgeons.
PURPOSE: This paper explores the causes of paediatric inguinal hernia (PIH) recurrence after single-port laparoscopic percutaneous extraperitoneal closure (SPLPEC).
METHOD: From January 2015 to December 2020, the clinical data of 3480 children with PIHs who underwent SPLPEC were retrospectively reviewed, including 644 children who underwent SPLPEC with a homemade single-hook hernia needle from January 2015 to December 2016 and 2836 children who underwent the SPLPEC with a double-hook hernia needle and hydrodissection from January 2017 to December 2020. There were 39 recurrences (including communicating hydrocele) during the 2-5 years of follow-up. The findings of redo-laparoscopy were recorded and correlated with the revised video of the first operation to analyse the causes of recurrence.
RESULT: Thirty-three males and 6 females experienced recurrence, and 8 patients had a unilateral communicating hydrocele. The median time to recurrence was 7.1 months (0-38). There were 20 cases (3.11%) in the single-hook group and 19 cases (0.67%) in the double-hook group. Based on laparoscopic findings, recurrence most probably resulted from multiple factors, including uneven tension of the ligation (10 cases), missing part of the peritoneum (14 cases), loose ligation (8 cases), broken knot (5 cases), and knot reaction (2 cases). All children who underwent repeat SPLPEC were cured by double ligations or reinforcement with medial umbilical ligament.
CONCLUSION: The main cause of recurrence is improper ligation. Tension-free and complete PIH ligation are critical to the success of surgery, which requires avoiding the peritoneum skip area and the subcutaneous and muscular tissues. Redo-laparoscopic surgery was suitable for the treatment of recurrent inguinal hernia (RIH). For giant hernias, direct ligation of the internal ring incorporating the medial umbilical ligament (DIRIM) may be needed.
In addition to conditions of the BASIC group, caregivers will also be asked to provide praise to their child for engaging in DSM over the 4 weeks. Additionally, when the caregiver completes caregiver check-ins in the DSM log, they will receive a prompt to also complete a praise check-in. The child's log will also include a virtual pet that evolves over time as he/she uses the log. As the child earns points, the pet will level up and grow over time.
Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
This protocol proposes a phase 1 trial combining oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy with chemotherapy in metastatic pancreatic cancer. Nine subjects (3 cohorts, 3 subjects/cohort) with metastatic pancreatic cancer will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels (cohort 1- 1 x 1011 vp, cohort 2- 3 x 1011 vp, cohort 3- 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either through the stomach or duodenal wall using endoscopic ultrasound (EUS) guidance. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered \[18F\]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.

The primary endpoint is toxicity at day 21. A secondary endpoint is rates of ≥ grade 3 CTCAE adverse events. Exploratory endpoints include 1) intensity, persistence, and biodistribution of HSV-1 TK gene expression, and 2) association of immunological measurements (i.e., cytokine levels, NK cytolytic activity) with toxicity and clinical outcome.
One face-to-face session to be informed of the group they have been randomised into and Acceptance Based Support, followed by five 30-minute telephone sessions of Acceptance Based Support. Usual care continues as normal.
Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
Necrotising sialometaplasia (NSM) is a non-neoplastic lesion mainly arising in the minor salivary glands of the oral cavity. In the clinical features, NSM shows swelling with or without ulceration, and can mimic a malignant disease such as squamous cell carcinoma. Histopathologically, NSM usually shows the lobular architecture that is observed in the salivary glands. Additionally, acinar infarction and squamous metaplasia of salivary ducts and acini are observable. The aetiology of this lesion remains unknown, although it has a characteristic feature that sometimes requires clinical and histopathological differentiation from malignancy. In this study, we investigated upregulated genes in NSM compared with normal salivary glands, and focused on the TGF-β3 (TGFB3) gene. The results of the histopathological studies clarified that fibroblasts surrounding the lesion express TGF-β3. Moreover, in vitro studies using mouse salivary gland organoids revealed that TGF-β3 suppressed salivary gland cell proliferation and induced squamous metaplasia. We demonstrated a possible aetiology of NSM by concluding that increased TGF-β3 expression during wound healing or tissue regeneration played a critical role in cell proliferation and metaplasia. © 2024 The Pathological Society of Great Britain and Ireland.
There is provided a novel adenylate cyclase enzyme, the nucleotide sequence of which is set out in SEQ ID No. 1. The activity of the adenylate cyclase is uniquely regulated by calcineurin, a protein phosphatase. The calcineurin binding site has been identified at amino acids 503 to 610 of the novel adenylate cyclase. Regulation of the novel adenylate cyclase may be useful in treating certain disorders. Suitable regulators include agents which bind to the 503-610 amino acid site and include calcineurin, its activators, inhibitors and competitors and antibodies specific to that site. Specific disorders include neurological disorders such as Parkinsons' disease, cardiovascular disorders such as angina pectoris and tumors, especially ovarian tumors.
The survey will be hosted via QualtricsXM and accessible via an anonymous link. When participants open the survey, they will be presented with the survey's information sheet explaining the study's purpose and procedures. The information sheet will make it clear that completing the survey is voluntary and cadets may cease the survey at any time. Data from unfinished surveys will not be included in final analyses for any reports produced from this survey. Participants will complete demographics questions. Then, participants will answer injury reporting intentions and stigma questions, presented in a randomized order to reduce respondent fatigue. Participants will then watch a health promotion video that encourages reporting musculoskeletal injuries while in ROTC. Participants have the potential to be shown one of three videos: an officer-delivered health promotion, cadet-delivered health promotion, and a video of an officer exercising. Participants will be randomly assigned to one of the three videos using the in-built randomization function within Qualtrics. After watching the video, participants will answer the stigma and intentions questions again. After, participants will be asked to provide an email address that will be used to send them a link to complete the survey a second time. The follow-up portion will ask for their unique identifier as described above and have the participants answer the stigma and intentions questions again. All data will be de-identified when exporting responses from Qualtrics. No reference will be made to any individual participant in any way when presenting or reporting these data.